Keywords: GlaxoSmithKline, Benlysta, Tyverb, Roche, Herceptin, UK, NICE

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin

Article | 27 April 2012

Print This

There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health and Clinical ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in